A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with
relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1
CAR T cells that causes few or mild side effects in participants. Once the researchers find
this dose, it will test it in a new group of participants to see if it is effective in
treating their relapsed/refractory AML.